联合检测血清IL-23、甲胎蛋白、同工铁蛋白对原发性肝癌的诊断价值  

Value of Combined Estimation of IL-23,Alpha-fetoprotein and Acidic Isoferritin in the Diagnosis of Primary Hepatic Liver Cancer

作　　者：黄菁[1] 张永臣[1] 虞玲[1] 

机构地区：[1]东南大学附属第二医院,南京210003

出　　处：《现代检验医学杂志》2011年第1期124-126,共3页Journal of Modern Laboratory Medicine

摘　　要：目的探讨联合检测血清白细胞介素-23、甲胎蛋白、同工铁蛋白对原发性肝癌的诊断价值。方法采用ELISA和电化学发光免疫法检测60例健康人、39例肝硬化患者和59例原发性肝癌患者血清白细胞介素-23和甲胎蛋白含量，采用散射比浊法检测同工铁蛋白含量。结果原发性肝癌患者血清中白细胞介素-23、甲胎蛋白、同工铁蛋白阳性率分别为72.88％，76.27％和71.18％，显著高于对照组和肝硬化组（P〈0．01）。结论与甲胎蛋白同时检测血清白细胞介素-23和同工铁蛋白，对原发性肝癌的早期诊断具有重要价值。Objective To discuss the value of combined detection of IL-23,acidic isoferritin and alpha-fetoprotein in the di- agnosis of primary hepatic cancer. Methods The serum IL-23, AFP and AIF levels were determined respectively by ELISA,electrochemical luminescence immunoassay and immune nephelometry in 59 patients with primary hepatic cancer patients and 39 patients with liver cirrhosis ,and compared with those of the 60 normal control. Results In primary hepatic cancer patients,the positive rates of IL-23,AFP and AIF were 72.88%, 76.27% and 71.18% respectively,significantly higher to normal control and cirrhosis group （P〈0. 01）. Conclusion Combination assay of IL-23,AFP and AIF has important value in diagnosis of primary hepatic cancer.

关 键 词：原发性肝癌 白细胞介素-23 甲胎蛋白 同工铁蛋白 

分 类 号：R735.7[医药卫生—肿瘤] R730.45[医药卫生—临床医学]